Accéder au contenu
Merck

Correlation between improvement in functional signs and plethysmographic parameters during venoactive treatment (Cyclo 3 Fort).

International angiology : a journal of the International Union of Angiology (2011-05-28)
F A Allaert, C Hugue, M Cazaubon, J M Renaudin, T Clavel, P Escourrou
RÉSUMÉ

The aim of this study was to compare the change in functional signs of venous insufficiency and venous refilling time measured by mercury strain-gauge plethysmography under the effects of the combination of Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid (Cyclo 3 Fort). An open-label clinical trial conducted in 65 women presenting with CEAP class C2s and C3s assessment criteria. At D0 and D28, functional signs were measured on a visual analog scale (VAS), venous refilling time by mercury strain-gauge plethysmography and venous reflux by echo-Doppler method. Under treatment, venous refilling time increased from 11.7±4 s to 13.8±4.4 s with Δ of 26% (P<0.0001) and the percentage of patients showing improvement of functional symptoms ≥30% was significantly correlated (P=0.04) with the percentage of patients presenting an improvement in venous refilling time ≥10%. Improvement in subjective functional signs under treatment with Cyclo 3 Fort was correlated with objective plethysmographic parameter improvement. There-fore, this study contributes to objectively document the benefit of prescribing this venoactive drug to active women with CEAP class C2s to C3s.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hesperidin methyl chalcone